Paradoxical hypotension and bradycardia after intravenous arginine vasopressin

Journal of Clinical Pharmacology

Volumn 38, Issue 3, 1998, Pages 283-286

  Kraft, Walter ^a   Greenberg, Howard E ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; OCTREOTIDE; PEPTIDE HORMONE;

ADULT; ARTICLE; BRADYCARDIA; CASE REPORT; DRUG EFFECT; ELECTROCARDIOGRAPHY; ESOPHAGUS VARICES BLEEDING; FEMALE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; HYPOTENSION; HYPOXIA; INTRAVENOUS DRUG ADMINISTRATION; OXYGEN SATURATION; SCLEROTHERAPY; SPLANCHNIC BLOOD FLOW;

EID: 0031919472     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04426.x     Document Type: Article

References (18)

1. Jutabha R, Jensen UGI: Bleeding in the patient with chronic liver disease. Med Clin North Am 1996;80:1035-1068.
2. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. New Engl J Med 1996;334:246-254.
3. Hanish E, Doertenbach J, Usadel KH: Somatostatin in acute bleeding oesophageal varices. Drugs 1992;44(suppl 2):24-35.
4. Cowley A: Vasopressin and blood pressure regulation. Clin Physiol Biochem 1988;6:150-162.
5. Irey NS: When is a disease drug induced? In, Riddel RH (ed.): Pathology of Drug-Induced and Toxic Diseases. New York: Churchill Livingston, 1982;1-18.
6. Kramer MS: Difficulties in assessing the adverse effects of drugs. Br J Clin Pharmacol 1981;11 (suppl 1):105S-110S.
7. Reynolds JE (ed.): Martindale: The Extra Pharmacopoeia. Thirtieth edition. London: The Pharmaceutical Press, 1993.
8. Berk JL, Hagen BA, Fried VJ: The effect of vasopressin on oxygen availability. Ann Surg 1979;189:439-441.
9. Liard JF, Deriaz O, Schelling P, Thibonnier M: Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs. Am J Physiol 1982;243:H663-H669.
10. Gimson AE, Westaby D, Hegarty J, Watson A, Williams R: A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986;6:410-413.
11. Drapanas T, Crowe CP, Shim W, Schenck WG: The effect of pitressin on cardiac output and coronary, hepatic and intestinal blood flow. Surg Gynecol Obstet 1961;113:484-489.
12. Moreno-Sanchez D, Casis B, Martin A, Ortiz P, Castellano G, Munoz MT, et al: Rhabodomyolysis and cutaneous necrosis following intravenous vasopressin infusion. Gastroenterology 1991;101:529-532.
13. Fogel R, Knauer C, Andres LL, Mahal AS, Stein DE, Kemeny MJ, et al: Continuous intravenous vasopressin in active upper gastrointestinal bleeding. Ann Intern Med 1982;96:565-569.
14. Abboud FM, Floras JS, Aylward PE, Guo GB, Gupta BN, Schmid PG: Role of vasopressin in cardiovascular and blood pressure regulation. Blood Vessels 1990;27:106-115.
15. Matsuguchi H, Schmid PF: Acute interaction of vasopressin and neurogenic mechanisms in DOC-salt hypertension. Am J Physiol 1982;242:H37-H43.
16. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds.): Harrison's Principles of Internal Medicine. Thirteenth edition. New York: McGraw-Hill, 1994.
17. Cello JP, Chan MF: Octreotide therapy for variceal hemorrhage. Digestion 1993;54(suppl 1):20-26.
18. Hardman J, Limbird L (eds.): Goodman & Gilman's The Pharmacologic Basis of Therapeutics. Ninth edition. New York: McGraw-Hill, 1996.